Eli Lilly and Company (NYSE:LLY) Shares Purchased by Azimuth Capital Investment Management LLC

Azimuth Capital Investment Management LLC boosted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 53.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 64,843 shares of the company's stock after acquiring an additional 22,603 shares during the quarter. Eli Lilly and Company accounts for approximately 1.9% of Azimuth Capital Investment Management LLC's holdings, making the stock its 5th largest position. Azimuth Capital Investment Management LLC's holdings in Eli Lilly and Company were worth $50,059,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Highline Wealth Partners LLC boosted its position in Eli Lilly and Company by 80.0% in the fourth quarter. Highline Wealth Partners LLC now owns 45 shares of the company's stock worth $35,000 after purchasing an additional 20 shares during the last quarter. Kovitz Investment Group Partners LLC lifted its stake in shares of Eli Lilly and Company by 117.1% in the 3rd quarter. Kovitz Investment Group Partners LLC now owns 46,132 shares of the company's stock worth $41,000 after purchasing an additional 24,879 shares during the period. FPC Investment Advisory Inc. boosted its holdings in shares of Eli Lilly and Company by 358.3% in the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock worth $45,000 after buying an additional 43 shares during the last quarter. Prudent Man Investment Management Inc. purchased a new stake in Eli Lilly and Company during the fourth quarter valued at approximately $48,000. Finally, Compass Financial Services Inc purchased a new stake in Eli Lilly and Company during the fourth quarter valued at approximately $50,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Up 1.5 %

LLY stock traded up $10.71 during trading on Friday, hitting $731.62. The company had a trading volume of 3,599,692 shares, compared to its average volume of 3,386,382. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53. The company has a 50 day simple moving average of $837.05 and a 200-day simple moving average of $822.87. The firm has a market capitalization of $693.70 billion, a P/E ratio of 62.48, a PEG ratio of 1.40 and a beta of 0.51. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. As a group, research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the firm's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares of the company's stock, valued at $4,778,521.60. This trade represents a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.13% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on LLY shares. Leerink Partners set a $950.00 price objective on Eli Lilly and Company in a research note on Friday, January 17th. Wells Fargo & Company upped their price target on Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Truist Financial lifted their price objective on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a research report on Monday, February 3rd. Morgan Stanley reduced their target price on shares of Eli Lilly and Company from $1,146.00 to $1,124.00 and set an "overweight" rating for the company in a report on Wednesday. Finally, Berenberg Bank set a $970.00 price target on shares of Eli Lilly and Company in a report on Thursday, January 16th. Two analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $1,017.67.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.